Full-Time

Head of In Vivo and Translational Sciences

Posted on 7/14/2025

Foresite Labs

Foresite Labs

1-10 employees

Creates AI-driven science-focused startups

Compensation Overview

$200k - $325k/yr

Boston, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • 15+ years of industry experience in biologics-based preclinical drug development (e.g., antibodies, ADCs)
  • Hands-on leadership of in vivo pharmacology studies from mouse PoC through IND-enabling work
  • Deep expertise in small and large animal pharmacology and toxicology, including non-human primates
  • Proven ability to work with cross-functional stakeholders in a dynamic, fast-paced environment
  • Experience managing external partners and CROs, especially in regulated (GLP) contexts
  • Entrepreneurial, data-driven, and collaborative. Thrives in ambiguity and energized by early-stage innovation
  • Broad therapeutic experience is essential to succeed in this role
Responsibilities
  • Oversee the design of in vivo studies across species (mouse, non-human primates, etc.), dosing paradigms (single/multi-dose), and modalities
  • Define performance criteria and key decision points to guide program progression from small animal to large animal models and development candidate nomination
  • Drive the preclinical path from early proof-of-concept to IND-enabling studies, establishing clear milestone gating strategies
  • Lead evaluation and interpretation of pharmacokinetics, pharmacodynamics, and biodistribution across multiple programs and platforms
  • Lead CRO selection and strategic relationship management for non-human primate studies
  • Provide scientific oversight across portfolio programs, guiding both internal and partner teams

Foresite Labs creates new startups at the crossroads of AI/machine learning and science. It turns scientific ideas into ventures by combining AI, data science, and rigorous methods to speed discovery. Projects are run by a single accountable leader with a Review Committee that allocates capital and guides direction, emphasizing transparency and focus. The goal is to turn rigorous scientific work into scalable companies that advance science and benefit humanity.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

Pleasanton, California

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $1B for Xaira Therapeutics via top VCs like Sequoia and NEA.
  • Hired experts like Mary Helen Black from J&J for genomics leadership.
  • Foresite Capital's $3.5B AUM supports 50+ IPOs and 58 FDA approvals.

What critics are saying

  • Xaira Therapeutics outcompetes with proprietary ML models in 12-24 months.
  • Executive hires strain resources as Capital prioritizes VC in 6-12 months.
  • Uplaksh Kumar's GRAIL failures erode scaling credibility in 12-18 months.

What makes Foresite Labs unique

  • Foresite Labs incubates Alumis for precision immune disease therapies using data analytics.
  • Integrates AI, data science, and analytics to accelerate scientific discovery uniquely.
  • Builds data ecosystem across portfolio to fuel AI breakthroughs in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Company Equity

Company News

Business Wire
Apr 24th, 2024
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development

Xaira Therapeutics launches to deliver transformative medicines by advancing and harnessing AI for drug discovery and development.

Business Wire
Apr 23rd, 2024
Xaira Therapeutics Launches To Deliver Transformative Medicines By Advancing And Harnessing Ai For Drug Discovery And Development

SAN FRANCISCO--(BUSINESS WIRE)--Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched with more than $1 billion of committed capital from lead investors ARCH Venture Partners and Foresite Capital, joined by F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, among others. Xaira brings together three core elements: advanced machine learning research, expansive data generation to power new models, and robust therapeutic product development. With leading talent and capabilities in each area, Xaira is building a platform for drug discovery and development that will advance multiple drug programs and unlock biological understanding to inform future discovery. Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira was co-founded by Dr

Yahoo Finance
Aug 10th, 2023
Foresite Labs Welcomes Dr. David Weinreich as Operating Partner

SAN FRANCISCO, August 10, 2023 --( BUSINESS WIRE )-- Foresite Labs today announced the appointment of David Weinreich, MD, MBA, as an operating partner.

Business Wire
Dec 1st, 2022
Foresite Labs Appoints Ian Tong, Md And Former Stanford School Of Medicine Professor, As Chief Clinical Officer | Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Today, Foresite Labs announced the addition of Ian Tong, MD to the team as its first chief clinical officer. Tong will work with Foresite Labs and Foresite Capital to improve access to equitable and effective healthcare at the intersection of technology and care delivery. Created in 2019, Foresite Labs’ mission is to found, build and scale life sciences initiatives at the intersection of healthcare and data science.Early in his career, Tong became an advocate for equitable healthcare access. As a clinical educator at the Stanford University School of Medicine, Tong co-directed the Arbor Free Clinic and pioneered early telemedicine outreach at the Veterans Affairs Palo Alto Health Care System. He also founded the Health Resource Initiative for Veterans Everywhere THRIVE program, which was awarded the national VA Secretary’s award for outstanding service to homeless Veterans. Tong holds his MD from The University of Chicago-Pritzker School of Medicine and is board certified in Internal Medicine.After leaving Stanford in 2013, he joined Doctor On Demand as the founding medical director and led the practice for the last six years as its chief medical officer and president of the professional corporation

Business Wire
Oct 18th, 2022
Foresite Labs Appoints Mary Helen Black, Former Johnson Johnson Department Head, To Vice President And Head Of Human Genomics

SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Today, Foresite Labs is pleased to announce the appointment of Mary Helen Black as its new vice president and head of genomics. She will focus on leading her team to generate evidence and insights from large-scale clinical and genomic data to support new and early ventures. Created in 2019, Foresite Labs’ mission is to found, build and scale life sciences initiatives at the intersection of healthcare and data science. Prior to joining Foresite Labs, Black was the head of Population Analytics, Computational Sciences, at The Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, she led the Johnson & Johnson partnership with UK Biobank and other major pharmaceutical companies to perform whole genome sequencing in half a million individuals and generate proteomics on more than 50,000 individuals in the UK. This dataset represents the world’s largest single release of whole genome sequencing data. The insights she led continue to be used to drive therapeutic development and inform clinical trial design

INACTIVE